Matteo Bellone

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 91 publications

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Journal: Clinical lung cancer

Published: January 11, 2026

PD1-IL2v expands and induces effector CD8+ TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.

PD1-IL2v expands and induces effector CD8+ TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 22, 2025

Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression.

Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression.

Journal: Cancer research

Published: June 25, 2025

A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model.

A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model.

Journal: Cancer discovery

Published: June 24, 2025

Diagnostic Accuracy of Fully Hybrid PET/MRI with [68Ga]Ga-PSMA-11 and [68Ga]Ga-RM2 in Detecting Primary Prostate Cancer: A Phase 2 Trial with Histology as Gold Standard.

Diagnostic Accuracy of Fully Hybrid PET/MRI with [68Ga]Ga-PSMA-11 and [68Ga]Ga-RM2 in Detecting Primary Prostate Cancer: A Phase 2 Trial with Histology as Gold Standard.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: February 25, 2025

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 06, 2024

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma.

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma.

Journal: Blood

Published: July 31, 2024

Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [18F]AlF2+ method.

Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [18F]AlF2+ method.

Journal: EJNMMI radiopharmacy and chemistry

Published: January 03, 2024

Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma.

Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma.

Journal: Nature communications

Published: December 26, 2023

Leveraging the Tumor Immune Microenvironment To Overcome Genitourinary Cancers.

Leveraging the Tumor Immune Microenvironment To Overcome Genitourinary Cancers.

Journal: European urology oncology

Published: April 04, 2023

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders.

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders.

Journal: Leukemia

Published: December 31, 2022

Cancer immunity and immunotherapy beyond COVID-19.

Cancer immunity and immunotherapy beyond COVID-19.

Journal: Cancer immunology, immunotherapy : CII

Published: September 06, 2022

Showing 1-12 of 91

Last Updated: 09/26/2026